Citations

Clear

1828 citation(s) found for "Su, Emily".

Appraisal of immunoglobulin free light chain as a marker of response
Dispenzieri, Angela , Zhang, Lijun , Katzmann, Jerry A., Snyder, Melissa R. , Blood, Emily, DeGoey, Roberta, Henderson, Kimberly J., Kyle, Robert A. , Oken, Martin M., Bradwell, A.R. , Greipp, Philip R., Dispenzieri, Angela

Mayo Clinic

Blood | March 26, 2008 | Volume: 111 | Issue: 10 | Pages: 4908-4915

10.1182/blood-2008-02-138602 | PMID 18364469 Get It

AbstractThe immunoglobulin free light chain (FLC) assay is an invaluable tool for following patients with oligosecretory plasma cell dyscrasia. Baseline values have also been shown to be prognostic in all plasma cell disorders tested. A looming question, however, is the role it should play in following myeloma patients with disease that is measurable using serum and urine electrophoresis. We used the data and stored samples from a mature Eastern Cooperative Oncology Group clinical trial (E9486) to assess serum levels of FLC at baseline and after 2 months of alkylator-based therapy. For serial determinations, the absolute level of involved serum FLC or the difference of the involved and uninvolved FLC is preferred over the ratio of involved to uninvolved FLC. FLC response after 2 months of therapy was superior to early M-protein measurement to predict overall response. The ideal cut-point for FLC change appears to be between 40% and 50% reduction. The correlation between serial measurements of serum FLC and urine M-protein is inadequate to abolish the serial 24-hour urine protein. Although baseline values of FLC are prognostic in newly diagnosed myeloma patients, serial measurements do not appear to have added value in patients who have M-proteins measurable by electrophoresis.
O2–03–03: Selective T1‐weighted enhancement of individual Alzheimer's disease amyloid plaques using an antibody fragment against Aβ42 as a magnetic resonance molecular imaging contrast agent
Poduslo, Joseph F., Ramakrishnan, Muthu, Wengenack, Thomas M., Curran, Geoffry L., Gilles, Emily J., Kandimalla, Karunya K. , Ramı́rez-Alvarado, Marina , Garwood, Michael , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | June 4, 2007 | Volume: 3 | Issue: 3S_Part_3 | Pages: No page available

10.1016/j.jalz.2007.04.028 Get It

In Vitro Effects of Antimicrobial Agents on Planktonic and Biofilm Forms of Staphylococcus lugdunensis Clinical Isolates
Frank, Kristi L. , Reichert, Emily J., Piper, Kerryl E., Patel, Robin , Patel, Robin

Mayo Clinic

Antimicrobial Agents and Chemotherapy | December 12, 2006 | Volume: 51 | Issue: 3 | Pages: 888-895

10.1128/aac.01052-06 | PMID 17158933 Get It

ABSTRACT Staphylococcus lugdunensis is an atypically virulent coagulase-negative staphylococcal species associated with acute and destructive infections that often resemble Staphylococcus aureus infections. Several types of infection caused by S. lugdunensis (e.g., native valve endocarditis, prosthetic joint infection, and intravascular catheter infection) are associated with biofilm formation, which may lead to an inability to eradicate the infection due to the intrinsic nature of biofilms to resist high levels of antibiotics. In this study, planktonic MICs and MBCs and biofilm bactericidal concentrations of 10 antistaphylococcal antimicrobial agents were measured for 15 S. lugdunensis isolates collected from patients with endocarditis, medical device infections, or skin and soft tissue infections. Planktonic isolates were susceptible to all agents studied, but biofilms were resistant to high concentrations of most of the drugs. However, moxifloxacin was able to kill 73% of isolates growing in biofilms at ≤0.5 μg/ml. Relative to the effect on cell density, subinhibitory concentrations of nafcillin substantially stimulated biofilm formation of most isolates, whereas tetracycline and linezolid significantly decreased biofilm formation in 93 and 80% of isolates, respectively. An unexpected outcome of MBC testing was the observation that vancomycin was not bactericidal against 93% of S. lugdunensis isolates, suggesting widespread vancomycin tolerance in this species. These data provide insights into the response of S. lugdunensis isolates when challenged with various levels of antimicrobial agents in clinical use.
IC–P–037: In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques
Poduslo, Joseph F., Holasek, Silvina S., Ramakrishnan, Muthu, Gilles, Emily J., Curran, Geoffry L., Wengenack, Thomas M., Ramı́rez-Alvarado, Marina

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_22 | Pages: No page available

10.1016/j.jalz.2006.05.2242 Get It

O1–03–02: In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques
Poduslo, Joseph F., Holasek, Silvina S., Ramakrishnan, M., Gilles, Emily J., Curran, Geoffry L., Wengenack, Thomas M., Ramı́rez-Alvarado, Marina

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_1 | Pages: No page available

10.1016/j.jalz.2006.05.045 Get It

Advancing the Study of Stroke in Women
Hurn, Patricia D., Colton, Carol A. , Miller, Virginia M. , Zoppo, Gregory del, Elkind, Mitchell S.V. , Stern, Barney J. , Herrington, David M. , Ford-Lynch, Gwendolyn, Gorelick, Philip B. , James, Allison , Brown, Candice M. , Choi, Emily W. , Bray, Paul F. , Newby, L. Kristin , Simpkins, James, Bushnell, Cheryl , Goldstein, Larry B. , James, Andra H

Mayo Clinic

Stroke | July 21, 2006 | Volume: 37 | Issue: 9 | Pages: 2387-2399

10.1161/01.str.0000236053.37695.15 | PMID 16857945 Get It

Background and Purpose— Women have poorer outcomes from stroke than men. Women also have risk factors that are unique, including pregnancy and hormone therapy. Hormone therapy for postmenopausal replacement increased the risk of ischemic stroke according to results of the Women’s Health Initiative clinical trials. Based on the current understanding of the mechanisms of action of estrogen, the reasons for this increased risk are uncertain. One method to better understand the reasons for this increased risk is to re-evaluate estrogen’s role in the neurovascular unit, simplistically comprised of the neurons, glia, and endothelial cells, as well as the processes of inflammation, and hemostasis/thrombosis. Besides the role of estrogen there are many gaps of knowledge about issues specific to women and stroke. Summary of Review— A multidisciplinary workshop was held in August 2005 to summarize the current evidence for estrogen and, more generally, stroke in women, and to provide recommendations for future basic, preclinical, and clinical research studies. Conclusions— These studies may ultimately change the approach to stroke prevention and treatment in women.
Real-Time PCR in Clinical Microbiology: Applications for Routine Laboratory Testing
Espy, Mark J., Uhl, J. R., Sloan, Lynne M., Buckwalter, Seanne P., Jones, Mary F. , Vetter, Emily A., Yao, Joseph D. , Wengenack, Nancy L. , Rosenblatt, Jon E., Cockerill, F. R., Smith, T. F., Cockerill, Franklin R.

Mayo Clinic

Clinical Microbiology Reviews | July 17, 2006 | Volume: 19 | Issue: 3 | Pages: 595-595

10.1128/cmr.00022-06 Get It

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications
González-Paz, Natalia, McClure, Rebecca F., Blood, Emily, Oken, Martin M., Ness, Brian Van, James, C. David , Kurtin, Paul J. , Henderson, Kimberly J., Ahmann, Gregory , Lacy, Martha Q. , Dispenzieri, Angela , Greipp, Philip R., Fonseca, Rafaël , Chng, Wee Joo , Gertz, Morie A. , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | July 14, 2006 | Volume: 109 | Issue: 3 | Pages: 1228-1232

10.1182/blood-2006-05-024661 | PMID 16840723 Get It

Abstract The biological and clinical implications of p16 gene methylation in multiple myeloma (MM) are still unclear despite previous studies. In this comprehensive study, using methylation-specific PCR (MS-PCR), we show that p16 methylation is relatively common and occurs in monoclonal gammopathy of undetermined significance (MGUS; n = 17), smoldering multiple myeloma (SMM; n = 40), and MM (n = 522) at a prevalence of 24%, 28%, and 34%, respectively. However, p16 methylation does not appear to affect gene expression level. In a large cohort of patients with long-term follow-up information (n = 439), there was no difference in overall survival between patients with or without p16 methylation. We also found no association between p16 methylation and the main cytogenetic categories, although it was more common among patients with 17p13.1 deletions (p53 locus), a genetic progression event in MM. In addition, p16 methylation has no apparent effect on the cycle because there was also no difference in the plasma cell labeling index (a direct measurement of proliferation) between patients with and without p16 methylation. Our results question a major role for p16 methylation in the oncogenesis of the PC neoplasm, and we now believe p16 methylation may be a marker for overall epigenetic changes associated with disease progression, with no obvious direct biological or clinical consequences.
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Richardson, Paul G. , Blood, Emily, Mitsiades, Constantine S. , Zeldenrust, Steven R., Alsina, Melissa , Schlossman, Robert, Rajkumar, S. Vincent , Desikan, K.R., Hideshima, Teru , Munshi, Nikhil C. , Kelly-Colson, Kathleen, Doss, Deborah, McKenney, Mary, Gorelik, Svetlana G. , Warren, Diane, Freeman, Andrea, Wu, Anfang, Olesnyckyj, Marta, Wride, Kenton, Dalton, William S. , Zeldis, Jerome B. , Weller, Edie, Richardson, Paul Gerard Guy , Jagannath, Sundar , Rich, Rebecca L. , Knight, Robert , Anderson, Kenneth C. , Rajkumar, S Vincent

Mayo Clinic

Blood | July 14, 2006 | Volume: 108 | Issue: 10 | Pages: 3458-3464

10.1182/blood-2006-04-015909 | PMID 16840727 Get It

Abstract This multicenter, open-label, randomized phase 2 study evaluated 2 dose regimens of lenalidomide for relapsed, refractory myeloma. Seventy patients were randomized to receive either 30 mg once-daily or 15 mg twice-daily oral lenalidomide for 21 days of every 28-day cycle. Patients with progressive or stable disease after 2 cycles received dexamethasone. Analysis of the first 70 patients showed increased grade 3/4 myelo-suppression in patients receiving 15 mg twice daily (41% versus 13%, P = .03). An additional 32 patients received 30 mg once daily. Responses were evaluated according to European Group for Blood and Marrow Transplantation (EBMT) criteria. Overall response rate (complete, partial, or minor) to lenalidomide alone was 25% (24% for once-daily and 29% for twice-daily lenalidomide). Median overall survival in 30-mg once-daily and twice-daily groups was 28 and 27 months, respectively. Median progression-free survival was 7.7 months on once-daily versus 3.9 months on twice-daily lenalidomide (P = .2). Dexamethasone was added in 68 patients and 29% responded. Time to first occurrence of clinically significant grade 3/4 myelosuppression was shorter in the twice-daily group (1.8 vs 5.5 months, P = .05). Significant peripheral neuropathy and deep vein thrombosis each occurred in only 3%. Lenalidomide is active and well tolerated in relapsed, refractory myeloma, with the 30-mg once-daily regimen providing the basis for future studies as monotherapy and with dexamethasone.